Entelo Bio Raises $4 Million to Scale AI-Driven Platform for Movement and Ageing Disorders

New updates have been reported about Entelo Bio.

Entelo Bio has exited stealth with a $4 million funding round to expand its AI-enabled biology platform targeting movement and ageing-related conditions that affect an estimated 1.7 billion people worldwide. The round was led by Ananda Impact Ventures, with participation from The Creator Fund and a network of U.S. and European bio- and tech-focused angel investors, providing early institutional validation of Entelo Bio’s model and giving the company runway to deepen its infrastructure and partnerships.

The company has developed a proprietary combination of clinical networks, wet-lab capabilities and AI systems designed to generate high-quality human data and disease models for disorders ranging from chronic age-associated diseases to rare genetic movement conditions. Co-founder and CTO Prof. Adam Cribbs said Entelo Bio’s platform is focused on human physical resilience, using global clinical data inputs to drive AI discovery and then validate predictions in human-centric models, while CEO Dr. Peter Crane framed the strategy as operating at the intersection of AI and consumer-driven medicine to de-risk and co-develop new therapeutics with partners. Investors emphasized the defensibility and scalability of Entelo Bio’s data and infrastructure, highlighting its origins in multi-omics and computational biology research at the University of Oxford’s Botnar Institute for Musculoskeletal Sciences and its team’s experience from leading AIxBio companies, positioning the firm to play a foundational role in precision medicine for movement and ageing-related disease.